🚀 VC round data is live in beta, check it out!
Oncolytics Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oncolytics Biotech and similar public comparables like Precision BioSciences, Naturland Holding, Agenus, XSpray Pharma and more.
Oncolytics Biotech Overview
About Oncolytics Biotech
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Founded
1998
HQ
Employees
28
Website
Sectors
Financials (LTM)
EV
$107M
Oncolytics Biotech Financials
Oncolytics Biotech reported last 12-month revenue of $185K and negative EBITDA of ($28M).
In the same LTM period, Oncolytics Biotech generated $185K in gross profit, ($28M) in EBITDA losses, and had net loss of ($30M).
Revenue (LTM)
Oncolytics Biotech P&L
In the most recent fiscal year, Oncolytics Biotech reported revenue of — and EBITDA of ($24M).
Oncolytics Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $185K | XXX | — | XXX | XXX | XXX |
| Gross Profit | $185K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($28M) | XXX | ($24M) | XXX | XXX | XXX |
| EBITDA Margin | (15090%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (16927%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($30M) | XXX | ($22M) | XXX | XXX | XXX |
| Net Margin | (16020%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oncolytics Biotech Stock Performance
Oncolytics Biotech has current market cap of $115M, and enterprise value of $107M.
Market Cap Evolution
Oncolytics Biotech's stock price is $1.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $107M | $115M | 0.0% | XXX | XXX | XXX | $-0.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOncolytics Biotech Valuation Multiples
Oncolytics Biotech trades at 577.9x EV/Revenue multiple, and (3.8x) EV/EBITDA.
EV / Revenue (LTM)
Oncolytics Biotech Financial Valuation Multiples
As of March 18, 2026, Oncolytics Biotech has market cap of $115M and EV of $107M.
Equity research analysts estimate Oncolytics Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncolytics Biotech has a P/E ratio of (3.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $115M | XXX | $115M | XXX | XXX | XXX |
| EV (current) | $107M | XXX | $107M | XXX | XXX | XXX |
| EV/Revenue | 577.9x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (3.8x) | XXX | (4.4x) | XXX | XXX | XXX |
| EV/EBIT | (3.4x) | XXX | (4.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 577.9x | XXX | — | XXX | XXX | XXX |
| P/E | (3.9x) | XXX | (5.2x) | XXX | XXX | XXX |
| EV/FCF | (2.9x) | XXX | (5.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oncolytics Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oncolytics Biotech Margins & Growth Rates
Oncolytics Biotech's revenue in the last 12 month grew by 374%.
Oncolytics Biotech's revenue per employee in the last FY averaged $0.0M.
Oncolytics Biotech's rule of 40 is (14716%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oncolytics Biotech's rule of X is (14155%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Oncolytics Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 374% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (15090%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 40% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (14716%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (14155%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6118% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8623% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oncolytics Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Precision BioSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Naturland Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Agenus | XXX | XXX | XXX | XXX | XXX | XXX |
| XSpray Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Aardvark Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncolytics Biotech M&A Activity
Oncolytics Biotech acquired XXX companies to date.
Last acquisition by Oncolytics Biotech was on XXXXXXXX, XXXXX. Oncolytics Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oncolytics Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOncolytics Biotech Investment Activity
Oncolytics Biotech invested in XXX companies to date.
Oncolytics Biotech made its latest investment on XXXXXXXX, XXXXX. Oncolytics Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oncolytics Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oncolytics Biotech
| When was Oncolytics Biotech founded? | Oncolytics Biotech was founded in 1998. |
| Where is Oncolytics Biotech headquartered? | Oncolytics Biotech is headquartered in Canada. |
| How many employees does Oncolytics Biotech have? | As of today, Oncolytics Biotech has over 28 employees. |
| Who is the CEO of Oncolytics Biotech? | Oncolytics Biotech's CEO is Wayne Pisano. |
| Is Oncolytics Biotech publicly listed? | Yes, Oncolytics Biotech is a public company listed on Nasdaq. |
| What is the stock symbol of Oncolytics Biotech? | Oncolytics Biotech trades under ONCY ticker. |
| When did Oncolytics Biotech go public? | Oncolytics Biotech went public in 2001. |
| Who are competitors of Oncolytics Biotech? | Oncolytics Biotech main competitors are Precision BioSciences, Naturland Holding, Agenus, XSpray Pharma. |
| What is the current market cap of Oncolytics Biotech? | Oncolytics Biotech's current market cap is $115M. |
| What is the current revenue of Oncolytics Biotech? | Oncolytics Biotech's last 12 months revenue is $185K. |
| What is the current revenue growth of Oncolytics Biotech? | Oncolytics Biotech revenue growth (NTM/LTM) is 374%. |
| What is the current EV/Revenue multiple of Oncolytics Biotech? | Current revenue multiple of Oncolytics Biotech is 577.9x. |
| Is Oncolytics Biotech profitable? | No, Oncolytics Biotech is not profitable. |
| What is the current EBITDA of Oncolytics Biotech? | Oncolytics Biotech has negative EBITDA and is not profitable. |
| What is Oncolytics Biotech's EBITDA margin? | Oncolytics Biotech's last 12 months EBITDA margin is (15090%). |
| What is the current EV/EBITDA multiple of Oncolytics Biotech? | Current EBITDA multiple of Oncolytics Biotech is (3.8x). |
| What is the current FCF of Oncolytics Biotech? | Oncolytics Biotech's last 12 months FCF is ($36M). |
| What is Oncolytics Biotech's FCF margin? | Oncolytics Biotech's last 12 months FCF margin is (19663%). |
| What is the current EV/FCF multiple of Oncolytics Biotech? | Current FCF multiple of Oncolytics Biotech is (2.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.